Because the modes of action of TRAIL and HDACi are distinct, their combined use appears to lead to synergistic killing of many tumor types that are normally TRAIL resistant, including bladder cancer cells, renal cell carcinomas, and prostate cancer cells [25–30]. Here, TNFSF10 is linked to neoplasm.